(Q35918566)

11 August 2017

1 reference

title

Breakthroughs in the treatment and prevention of Clostridium difficile infection (English)

1 reference

11 August 2017

main subject

Clostridium difficile

0 references

1 reference

2

Dale N Gerding

1 reference

11 August 2017

Larry K Kociolek

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

10 February 2016

1 reference

Nature Reviews Gastroenterology & Hepatology

11 August 2017

published in

1 reference

11 August 2017

volume

13

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

150-160

1 reference

Clostridium difficile--more difficult than ever

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Multistate point-prevalence survey of health care-associated infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

The changing epidemiology of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Clostridium difficile infection among children across diverse US geographic locations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Burden of Clostridium difficile infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Burden of Clostridium difficile on the healthcare system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

The host immune response to Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Clostridium difficile infection in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Current state of Clostridium difficile treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Is fidaxomicin worth the cost? An economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Comparison of Photodynamic Therapy versus conventional antifungal therapy for the treatment of denture stomatitis: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

The potential of probiotics to prevent Clostridium difficile infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Prevention of Clostridium difficile Infection With Probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Duodenal infusion of donor feces for recurrent Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Treating Clostridium difficile infection with fecal microbiota transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Fatal Aspiration Pneumonia as a Complication of Fecal Microbiota Transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Weight gain after fecal microbiota transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Colonization for the prevention of Clostridium difficile disease in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Toxin B is essential for virulence of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Antibodies for treatment of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Treatment with monoclonal antibodies against Clostridium difficile toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

The prospect for vaccines to prevent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Clostridium difficile: development of a novel candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Concomitant Medical Conditions and Therapies Preclude Accurate Classification of Children With Severe or Severe Complicated Clostridium difficile Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Pediatric Clostridium difficile infection: 6-year active surveillance in a defined patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2015.220

Bovine colostrum in the management of nonorganic failure to thrive: a randomized clinical trial

31 March 2020

1 reference

12 December 2020

Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children

1 reference

12 December 2020

Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection

1 reference

12 December 2020

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection

1 reference

12 December 2020

Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis

1 reference

12 December 2020

10.1038/NRGASTRO.2015.220

Identifiers

DOI

1 reference

11 August 2017

1 reference